Bellevue Group AG Has $396.12 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Bellevue Group AG raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 10.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 9,930,245 shares of the company’s stock after acquiring an additional 946,011 shares during the period. Ionis Pharmaceuticals makes up 3.9% of Bellevue Group AG’s holdings, making the stock its 2nd largest position. Bellevue Group AG owned 7.04% of Ionis Pharmaceuticals worth $396,117,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Envestnet Asset Management Inc. grew its holdings in shares of Ionis Pharmaceuticals by 42.3% in the 1st quarter. Envestnet Asset Management Inc. now owns 82,320 shares of the company’s stock valued at $3,701,000 after buying an additional 24,489 shares during the period. Standard Life Aberdeen plc grew its holdings in shares of Ionis Pharmaceuticals by 8.5% in the 1st quarter. Standard Life Aberdeen plc now owns 5,197 shares of the company’s stock valued at $234,000 after buying an additional 405 shares during the period. Alliancebernstein L.P. grew its holdings in shares of Ionis Pharmaceuticals by 11.9% in the 1st quarter. Alliancebernstein L.P. now owns 77,300 shares of the company’s stock valued at $3,475,000 after buying an additional 8,231 shares during the period. The PNC Financial Services Group Inc. grew its holdings in shares of Ionis Pharmaceuticals by 8.7% in the 1st quarter. The PNC Financial Services Group Inc. now owns 9,358 shares of the company’s stock valued at $420,000 after buying an additional 752 shares during the period. Finally, Swiss National Bank grew its holdings in shares of Ionis Pharmaceuticals by 1.7% in the 1st quarter. Swiss National Bank now owns 510,359 shares of the company’s stock valued at $22,946,000 after buying an additional 8,700 shares during the period. Institutional investors own 86.71% of the company’s stock.

In other Ionis Pharmaceuticals news, Director Joseph Klein III sold 4,334 shares of the stock in a transaction dated Thursday, July 15th. The shares were sold at an average price of $35.30, for a total value of $152,990.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.96% of the stock is owned by corporate insiders.

A number of equities analysts recently weighed in on IONS shares. BMO Capital Markets reduced their target price on shares of Ionis Pharmaceuticals from $70.00 to $68.00 and set an “outperform” rating for the company in a research note on Thursday, August 19th. SVB Leerink reduced their target price on shares of Ionis Pharmaceuticals from $41.00 to $38.00 and set a “market perform” rating for the company in a research note on Thursday, August 5th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating and set a $41.00 target price for the company in a research note on Monday, August 9th. Finally, Morgan Stanley reduced their price objective on shares of Ionis Pharmaceuticals from $35.00 to $33.00 and set an “underweight” rating for the company in a research note on Friday, July 16th. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $52.95.

Shares of IONS stock opened at $36.20 on Monday. The company has a debt-to-equity ratio of 2.13, a quick ratio of 7.54 and a current ratio of 7.62. The firm’s 50-day moving average is $37.93 and its 200-day moving average is $39.73. The stock has a market cap of $5.11 billion, a price-to-earnings ratio of -9.35 and a beta of 1.05. Ionis Pharmaceuticals, Inc. has a 52-week low of $34.43 and a 52-week high of $64.37.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, August 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.01). The firm had revenue of $126.00 million during the quarter, compared to the consensus estimate of $128.46 million. Ionis Pharmaceuticals had a negative net margin of 78.78% and a negative return on equity of 58.39%. The firm’s revenue for the quarter was down 13.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.18) earnings per share. Sell-side analysts predict that Ionis Pharmaceuticals, Inc. will post -1.81 EPS for the current fiscal year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases.

Further Reading: Forex

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.